Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries Dr. Matthew ...
Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...
Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback